[Clinical-neurophysiological study of efficacy of adaptol in discirculatory encephalopathy].
Sixty-eight patients, aged from 40 to 70 years, with discirculatory encephalopathy, I and II stages, have been examined. Thirty-five patients of the main group received non-benzodiazepine tranquilizer adaptol in dose 500 mg 2 times daily in addition to regular vasoactive treatment and 33 patients of the control group received only regular treatment. The following characteristics were assessed at baseline and after 1 month of treatment: complaints and neurological status, anxiety level (the Spielberger-Khanin scale), quality of life (SF-36) and parameters of P300 cognitive evoked potentials. To the end of treatment, there were the significant decrease of state and trait anxiety, improvement of quality of life, decrease of P300 latencies and increase of P300 amplitudes. No significant side-effects were seen, only 2 (5.7%) patients had transitory dyspepsia. In conclusion, adaptol in dose 1000 mg daily is effective and safe for the complex treatment of discirculatory encephalopathy of I and II stages.
E R
ER
Barantsevich
O V
OV
Posokhina
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001736:Biureas / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000139:chemically induced / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D001736:Biureas; C015979:mebikar